SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending due to a significant drop following a lowered sales outlook, sparking discussions about consumer spending and the company's value proposition. Community members are debating whether the dip is a buying opportunity or a sign of deeper issues with the brand, citing concerns about pricing, portion sizes, and competition in the fast-casual dining sector.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to raised FY25 EBITDA guidance, sparking optimism about the company's future profitability. The community is discussing the potential for a significant stock re-rating and a short squeeze, with some highlighting the low P/E ratio relative to the broader market. Discussions also involve potential catalysts like government appropriations and debt refinancing.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to upcoming Phase 3 data for its DMD treatment, with investors closely watching for positive results that could lead to FDA approval; community chatter reflects both excitement and apprehension, as the data represents a pivotal moment for the company. Community members also highlight BlackRock's substantial stake in Capricor. Some traders cite the potential for a significant short squeeze based on the stock's high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Reasons to Buy Pharma ETFs Now for a Healthy Portfolio

Pharma's Trump-Pfizer boost sparks momentum, making ETFs PPH, IHE, PJP & XPH attractive for defensive, undervalued growth plays.

Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

White House Press Secretary Karoline Leavitt said on Thursday that President Donald Trump is set to send out letters to 17 pharmaceutical company CEOs in the U.S., including Eli Lilly (LLY), giving them 60 days to address the global pricing disparity of drugs.“Other nations have been free-loading on U.S. innovation for far too long, and it is time they pay their fair share,” said Leavitt, reading out one of the letters, addressed to Eli Lilly CEO David A. Ricks.<a href="http://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dipped more than 1% in afternoon trade after the news broke. On Stocktwits, retail sentiment around the pharmaceutical giant remained in ‘bullish’ territory over the past day.Other pharma stocks also took a hit. Moderna (MRNA) extended its downtrend, dipping nearly 7%, AstraZeneca (AZN) slipped more than 3% and Pfizer (PFE) was down over 1%.&nbsp;The warning comes after Trump signed an executive order delivering ‘most favored nation’ prescription drug pricing for U.S. patients in May.The letter alleges that most of the proposals that the Trump administration has received to resolve the issue of drug pricing promised “more of the same, shifting blame, and requesting policy changes that would result in billions of dollars in handouts to the industry.”It outlines that drug makers have 60 days to achieve the following goals:- Extend the ‘most favored nation’ pricing to Medicaid- Guarantee ‘most favored nation’ pricing for newly launched drugs- Return increased revenues abroad to American patients and taxpayers- Provided for direct purchasing at ‘most favored nation’ pricing“But if you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,” warned the letter, adding that the Trump administration, U.S. Health Secretary Robert Kennedy Jr. and Centers for Medicare and Medicaid Services (CMS) administrator Mehmet Oz stand ready to implement these terms.&nbsp;According to the letter, the companies have till September 29 to comply.&nbsp;The VanEck Pharmaceutical ETF (PPH) dropped more than 2%, while the iShares U.S. Pharmaceutics ETF (IHE) edged 0.8% lower.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sec-chair-unveils-project-crypto-to-back-trump-push-for-us-crypto-dominance/choLhyMRdG4">SEC Chair Unveils ‘Project Crypto’ To Back Trump’s Push For US Crypto Dominance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Donald Trump gestures during a meeting with British Prime Minister Keir Starmer (not pictured) on July 28, 2025 in Turnberry, Scotland. (Photo by Christopher Furlong/Getty Images)

Trump To Issue 60-Day Warning Letters To Drugmakers Over Pricing 

The U.S. President is expected to send out these letters through his social media platform, Truth Social.

Equity

ETFs on the Move Post U.S.-China Trade Deal

Morgan Stanley’s Wilson addresses 8 key investor questions

Sandoz CEO Richard Saynor has reportedly stated that the proposal to introduce a Europe-wide list price for new medicines is "deeply flawed."Saynor <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-ceo-slams-eu-wide-drug-price-proposal-warns-us-tariffs-will-hurt-patient-2025-04-28/">told</a> Reuters that the proposal, put forth by Novartis and Sanofi in a<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/de921b3c-988c-4d60-aca1-def85c70d299"> letter</a> to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and will not address global pricing inequities."It made me smile, made me laugh," Saynor said of the proposal.Sanofi and Novartis, in a proposal submitted last week, alleged that European price controls on medicines hinder innovation and proposed a Europe-wide list price for new medicines within the range of U.S. net prices.Saynor believes that the Trump administration will drive down prices for brand-name medicines. Some form of U.S. price reform, he said, is inevitable. &nbsp;However, big pharmaceutical companies should not hike prices in Europe to compensate, he added.U.S. patients have long borne a disproportionate share of costs for innovative medicines, while large drugmakers maintain high margins, the Sandoz CEO argued, citing Amgen’s autoimmune treatment Enbrel, which costs $70,000 per patient per year in the U.S. compared to $7,000 per patient in Europe.Switzerland-based Sandoz makes generic and biosimilar drugs, which are also sold in the U.S.The company's North America President, Keren Haruvi, has been meeting with White House officials nearly every week to discuss pharmaceutical imports and the U.S. reliance on foreign drug production, Saynor said, according to Reuters.Sandoz could be forced to withdraw some products from the U.S. market if significant tariffs are imposed, he added.Earlier this month, Sandoz <a href="https://stocktwits.com/news-articles/markets/equity/sandoz-files-antitrust-lawsuit-against-amgen-seeks-damages/chfCP48Rbac">filed</a> an antitrust lawsuit against Amgen, Inc., (AMGN), alleging that the latter is blocking competition to its drug Enbrel by unlawfully purchasing certain patent rights.Sandoz’s Erelzi is a biosimilar of Amgen’s Enbrel, a medicine used to treat a range of inflammatory diseases.Sandoz alleged that Amgen blocked competition from more cost-effective biosimilar competitors, including Erelzi, which received approval from the U.S. Food and Drug Administration (FDA) in 2016, using certain patent rights to entrench its position in the market.Many Americans could benefit from the cost savings and expanded access resulting from the introduction of high-quality, more affordable biosimilar options, the company said.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/hsbc-double-downgrades-eli-lilly/chQx6M5RbhN">Eli Lilly Stock Gets A Double Downgrade And Price Target Cut By HSBC Over Valuation, Competition Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Swiss pharmaceuticals company Sandoz Group AG logo seen displayed in front of business webpage. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report

Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and will not address global pricing inequities.

Investors are most bearish in 30 years, BofA survey finds

Investing.com -- Investor sentiment has deteriorated to its most bearish point in three decades, according to the latest BofA Global Fund Manager Survey (FMS).

Pharma stocks up on US tariff exemptions but analyst flags a $46B import cost risk

Investing.com -- Pharmaceutical stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts cautioned that the sector is not in the clear, as targeted levies may still be on the horizon.

Shares of Xeris Biopharma Inc. surged more than 9.5% on Thursday, reaching their highest level since June 2021, driven by a better-than-expected revenue forecast for 2025 that fueled investor optimism.&nbsp;The rally came despite a slightly wider-than-expected quarterly loss, with retail sentiment increasingly bullish following the earnings release.Xeris reported an adjusted fourth-quarter loss of $0.03 per share, narrowly missing Wall Street expectations of a $0.02 loss.&nbsp;However, revenue for the period was $60.01 million, exceeding the consensus estimate of $58.54 million.&nbsp;The company's full-year guidance emerged as the key driver of market enthusiasm. Xeris expects 2025 revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.CEO John Shannon described 2024 as an "exceptional" year, as revenue surpassed $203 million to a record high.&nbsp;CFO Steven Pieper said record quarterly revenue of more than $60 million in&nbsp;Q4 contributed to a positive cash flow of $2 million and adjusted&nbsp;earnings before interest, taxes, depreciation, and amortization (EBITDA) of over $8 million.&nbsp;He added that the 2025 revenue outlook represents more than 30% growth at the midpoint.Xeris currently markets three key products: Recorlev for endogenous Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis.&nbsp;It is also advancing a pipeline of development programs, led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, alongside several early-stage programs leveraging its technology platforms.On Stocktwits, sentiment for Xeris turned 'extremely bullish' (89/100) and reached its highest score in a year, with message volume surging by 780% in the 24 hours to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/XERS_sentiment_and_message_volume_as_of_March_6_14ecb19082.png" alt="XERS sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>XERS sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user noted that the stock's long period of stagnation, "like 40 qtrs in the desert," had finally given way to momentum.&nbsp;<stembedurl>https://stocktwits.com/NobVega/message/607012972</stembedurl>Another speculated about the possibility of a buyout, suggesting that Xeris could attract an acquisition offer by the end of the year.<stembedurl>https://stocktwits.com/Finwizard61/message/607030000</stembedurl>Short interest in Xeris last stood at 6.9%, according to Koyfin data. The company's stock, which was falling after-hours on Thursday, has gained nearly 22% since the start of the year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

Shares of Esperion Therapeutics (ESPR) surged over 12% on Tuesday, marking their best session since early December, as the pharmaceutical company posted a strong fourth-quarter report that exceeded expectations.Esperion reported a quarterly loss of $0.11 per share, better than a consensus estimate of a $0.16 loss.&nbsp;Revenue came in at $69.1 million, surpassing expectations of $61.58 million.&nbsp;CEO Sheldon Koenig said Esperion expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe, as well as global expansion into key markets like Japan.Effective Jan. 29, 2025, the U.S. Department of Defense added Esperion’s NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) to its Uniform Formulary as preferred agents, covering nine million lives.&nbsp;The company also expanded its prescriber base, now reaching over 25,000 healthcare practitioners — a 10% increase from Q3.Esperion has initiated the development of two triple-combination products in the U.S., incorporating bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin.&nbsp;The company believes these formulations could offer low-density lipoprotein cholesterol (LDL-C) reductions exceeding 60%, positioning them as competitive alternatives to existing and emerging injectable and oral cholesterol-lowering therapies.Esperion said its Japanese partner, Otsuka Pharmaceutical Co., Ltd., has submitted a New Drug Application for bempedoic acid in the Asian country for the treatment of hypercholesterolemia and familial hypercholesterolemia.&nbsp;Otsuka anticipates approval and National Health Insurance pricing in the second half of 2025.H.C. Wainwright &amp; Co. reportedly maintained its $16.00 price target on Esperion, implying an 800% upside from current levels, according to Dow Jones newswires.On Stocktwits, sentiment remained ‘extremely bullish’ as message volume spiked 13% in the 24 hours to Tuesday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ESPR_sentiment_and_message_volume_as_on_March_4_4d838f95e8.png" alt="ESPR sentiment and message volume as on March 4.png" width="1316" height="316"><figcaption>ESPR sentiment and message volume as on March 4 | source: Stocktwits</figcaption></figure>One user speculated on the potential for growing royalties from international markets like Japan, Australia, and Israel.<stembedurl>https://stocktwits.com/theDeathStar/message/606790322</stembedurl>Another user suggested Otsuka could expand its partnership or buyout Esperion — rather than Daiichi Sankyo — on the back of its $20 billion cash reserves and stated plans for acquisitions this year.<stembedurl>https://stocktwits.com/djohnson591/message/606725247</stembedurl>Esperion originally signed a licensing agreement with Daiichi Sankyo Europe in 2019, granting exclusive rights to commercialize bempedoic acid products in the European Economic Area and Switzerland.<a href="https://stocktwits.com/symbol/ESPR">Esperion shares</a> remain down more than 20% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4

CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key markets.

SPDR Series Trust - SPDR Pharmaceuticals ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

XPH
SPDR Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XPH News

XPHSPDR Pharmaceuticals ETF